UTHR

United TherapeuticsB

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

Quote time unavailable

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$650.00

Analysis reference price unavailable

Analysis 2026-08-17 · RankAlpha Sentiment Codex

Most likely

Base case

50%

Probability

Target price

$540.00

Analysis reference price unavailable

Analysis 2026-08-17 · RankAlpha Sentiment Codex

B-

Bear case

25%

Probability

Target price

$425.00

Analysis reference price unavailable

Analysis 2026-08-17 · RankAlpha Sentiment Codex

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-08-17

AI commentary

News tone is mixed: Q2 EPS modestly exceeded estimates in stored earnings context, but revenue declined and core product trends weakened. The same stored context described an initially muted price reaction near the pre-earnings level. Social, options, short-interest, employee-review, and post-print analyst-revision data are unavailable, so this remains a moderate-confidence execution and regulatory monitoring setup.

RankAlpha Sentiment Codex - 2026-08-17

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-08-05catalystMixed Q2 execution keeps near-term expectations restrainedMedium impact

Q2 revenue declined 2% year over year to $783.3 million. Tyvaso DPI grew 4%, but nebulized Tyvaso declined 18%, total Tyvaso declined 4%, and Remodulin declined 6%, creating an execution and product-mix overhang [#SEC-8K-2026-08-05].

2026-12-31catalystTyvaso DPI commercial uptakeHigh impact

Management reported record Tyvaso DPI starts, referrals, commercial patients, and total patients at quarter-end, supporting a possible return to sequential portfolio growth if physician adoption continues [#SEC-8K-2026-08-05].

2027-12-31eventPotential nebulized Tyvaso approval in IPFHigh impact

United Therapeutics reported submission of an NDA for nebulized Tyvaso in IPF and described potential approval in 2027 as a major growth catalyst. Regulatory timing and approval outcome remain uncertain [#SEC-8K-2026-08-05].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-08-17 • Updated nightlySource: Internal modelMethodology